Navigation Links
FINRA Confirms China BCT's Corporate Name Change

LIUZHOU CITY, China, July 27 /PRNewswire-Asia-FirstCall/ -- China BCT Pharmacy Group, Inc., (OTC Bulletin Board: CNBI), ("China BCT" or the "Company"), a leading pharmaceutical distributor, retail pharmacy, and manufacturer of pharmaceutical products in Guangxi Province, China, today announced that the Financial Industry Regulatory Authority (FINRA) confirmed the Company's new corporate name, China BCT Pharmacy Group, Inc., effective July 22, 2010.

China BCT's former name was China Baicaotang Medicine Limited. There are no other changes to the Company's corporate structure, management team or business operations. China BCT will continue to be quoted on the Over the Counter Bulletin Board under the ticker symbol "CNBI."

"We believe that our new corporate name more clearly reflects our core business which integrates pharmaceutical distribution, pharmacy retailing, and pharmaceutical manufacturing. It is also simpler for customers and investors to recognize," commented Mr. Hui Tian Tang, Chairman and Chief Executive Officer of China BCT.

About China BCT

China BCT is engaged in pharmaceutical distribution, pharmacy retailing, and the manufacture of pharmaceuticals products through its subsidiaries Guangxi Liuzhou Baicaotang Medicine Limited, Hefeng Pharmaceutical Co. Limited, and Guangxi Liuzhou Baicaotang Medicine Retail Limited in Guangxi province, China. It operates a large regional retail network in Guangxi province, consisting of 125 directly owned retail stores in Guangxi province and currently over 8,000 products are distributed through the Company's wholesale distribution network. For more information, please visit

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( ). Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this presentation.

    For more information, please contact:

    Company Contact:
     Ms. Shelly Zhang, Chief Financial Officer
     China BCT Pharmacy Group, Inc.
     Tel:   +86-772-363-8318

    Investor Relations Contact:
     Mr. Crocker Coulson, President
     CCG Investor Relations
     Tel:   +1-646-213-1915

     Ms. Elaine Ketchmere
     VP of Financial Writing
     Tel:   +1-310-954-1345

     CCG Investor Relations

SOURCE China BCT Pharmacy Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CardioGenics Holdings Inc. Provides Update on FINRA Submission Regarding Name Change
2. AVAC Praises CAPRISA 004 Trial Collaborators and Participants for Historic Study - Trial Confirms Promise of ARV-Based Microbicides
3. Perrigo Company Confirms Patent Challenge for Clobetasol Propionate Emulsion Foam
4. Watson Confirms Renvela® for Oral Suspension Patent Challenge
5. Lilly Confirms Date and Conference Call for Second-Quarter 2010 Financial Results Announcement
6. Watson Confirms Columbia Laboratories Shareholder Approval of Proposed Acquisition of Progesterone-related Assets
7. Watson Confirms Columbia Laboratories Filing of Definitive Proxy Relating to Watsons Acquisition of U.S. Rights to CRINONE® Progesterone Gel Product Line
8. Delcath Reconfirms Presentation During American Society of Clinical Oncology 2010 Annual Meeting in Chicago
9. GAO Confirms Payment Delays to Medical Equipment Providers; Questions Arise as to Whether Medicare Can Implement Reforms
10. Watson Confirms EVISTA(R) Patent Challenge
11. Watson Confirms Trilipix(R) Patent Challenge
Post Your Comments:
(Date:11/26/2015)... 2015 Research and Markets ( ) has ... Market Outlook to 2019 - Rise in Cardiac Disorders and ... report to their offering. Boston ... scientific and others. --> The ... Boston scientific and others. ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... Global Cell Surface Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Therapeutic Drug Monitoring (TDM) Market: Supplier ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion is a set of ... With ProSidebar: Fasion, video editors can easily add an informative sidebar to any FCPX ... Utilize presets featuring self-animating drop zones, lines, bars, and text with the ease ...
(Date:11/27/2015)... ... 2015 , ... A simply groundbreaking television series, "Voices in America", which is ... an array of issues that are presently affecting Americans. Dedicated to providing the world ... is changing the subjects consumers focus on, one episode at a time. , ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... and prominent nonprofit healthcare organizations in the country. They have overseen financial turnarounds, ... and helped advance the healthcare industry as a whole through their advocacy and ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity ... have come together on Thanksgiving Day to share the things that they are ... the Serenity Point YouTube channel, patients displayed what they wrote on index cards, ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
Breaking Medicine News(10 mins):